Blue Cross Blue Shield/Blue Care Network of Michigan
Medication Authorization Request Form

Blue Cross Blue Shield Blue Care Network of Michigan

Nonprofit corporations and independent licensees of the Blue Cross and Blue Shield Association

This form is to be used by participating physicians to obtain coverage for **drugs covered under the medical benefit**. For commercial members only, please complete this form and submit via fax to 1-877-325-5979. If you have any questions regarding this process, please contact BCBSM Provider Relations and Servicing or the Medical Drug Helpdesk at 1-800-437-3803 for assistance.

PATIENT INFORMATION		PHYSICIAN INFORMATION
Name		**Name**
ID Number		**Specialty**
D.O.B.	_____/_____/_____ MM/DD/YYYY ❑Male ❑Female	**Address**
Diagnosis		**City /State/Zip**
Drug Name	**Stelara SC**	**Phone:** **Fax:**
Dose and Quantity		**NPI**
Directions		**Contact Person**
Date of Service(s)		**Contact Person** **Phone / Ext.**

STEP 1: DISEASE STATE INFORMATION

Required Demographic Information:

Patient Weight: _____*kg*

*Patient Height:*_____*ft* _____*inches*

Will the provider be administering the medication to the FEP member within the health plan's geographic service area?

❑ Yes ❑ No *If No, a prior authorization is not required through this process.*

Prior authorizations are required for FEP members that will be serviced by a provider within the health plan's geographic service area. If you are not a provider in the geographic service area, please contact the health plan for questions regarding the FEP member's benefit requirements.

Is this member's FEP coverage primary or secondary coverage?

❑ If primary, continue with question set.

❑ If secondary, **an authorization is not needed through this process. Please contact the member's primary coverage for determination of benefit and additional information.**

Site of Care:

A. At what location will the member be receiving the requested medication?

❑ Physician's office, home infusion, non-hospital affiliated ambulatory infusion center.

❑ Outpatient hospital infusion center. Please provide the name of the infusion center and rationale why the patient must receive this medication in a hospital outpatient setting. _____

_____

❑ Other. Please specify. _____

Criteria Questions:

1. Has the patient been on Stelara continuously for the last **6 months**, excluding samples? ***Please select answer below:***

   ❑ **YES** – this is a PA renewal for **CONTINUATION** of therapy, please answer the questions on **Continuation section.**

   ❑ **NO –** this is **INITIATION** of therapy, please answer the questions below:

2. Has the patient been tested for latent tuberculosis (TB)? ❑Yes* ❑No

   If YES, was the result of the test positive or negative for TB infection? ❑Negative ❑Positive*

   If POSITIVE, has the patient completed treatment or is the patient currently receiving treatment for latent TB? ❑Yes ❑No

3. Does the patient have any active infections including active TB or hepatitis B virus (HBV) infection? ❑Yes ❑No

4. Will the patient be given live vaccines while on Stelara? ❑Yes ❑No

5. Will Stelara be used in combination with another biologic *disease-modifying antirheumatic drug (DMARD) or targeted synthetic DMARD? ❑Yes* ❑No

   If YES, please specify: _____

DMARDs: Actemra, Avsola, Cimzia, Cosentyx, Enbrel, Entyvio, Humira, Ilumya, Inflectra, Kevzara, Kineret, Olumiant, Orencia, Otezla, Remicade, Renflexis, Riabni, Rinvoq, Rituxan, Ruxience, Siliq, Simponi/Simponi Aria, Skyrizi, Taltz, Tremfya, Truxima, and Xeljanz/Xeljanz XR

6. What is the patient's diagnosis?

❑ Crohn's Disease (CD)

a. Does the patient have a diagnosis of moderate to severely active Crohn's disease? ❑Yes ❑No

b. Does the patient have a contraindication or have they had either an inadequate response or intolerance to at least one conventional therapy option? ❑Yes ❑No

c. Will the patient's first dose be given an IV infusion? ❑Yes ❑No

d. What is the patient's weight in either pounds (lbs) or kilograms (kg)? ***Please select answer below:***

❑**55kg (121lbs) or less**: Does the prescriber agree to administer 260mg for the initial IV infusion? ❑Yes ❑No

❑**Greater than 55kg (121lbs) to 85kg (187lbs)**: Does the prescriber agree to administer 390mg for the initial IV infusion? ❑Yes ❑No

❑**Greater than 85kg (187lbs)**: Does the prescriber agree to administer 520mg for the initial infusion? ❑Yes ❑No

e. Following the initial IV infusion, does the prescriber agree to administer Stelara within the FDA labeled maintenance dose of 90mg subcutaneously every eight weeks? ❑Yes ❑No

❑ Plaque Psoriasis (PsO)

a. Does the patient have a diagnosis of moderate to severe plaque psoriasis? ❑Yes ❑No

b. Does the patient have an intolerance or contraindication or have they had an inadequate treatment response to conventional systemic therapy? ***Please select answer below:***

❑ Inadequate response ❑ Intolerance or contraindication ❑ Has not tried conventional systemic therapy

c. Does the patient have an intolerance or contraindication or have they had an inadequate treatment response to phototherapy? ***Please select answer below:***

❑ Inadequate response ❑ Intolerance or contraindication ❑ Has not tried phototherapy

d. **Age 6-17**: What is the patient's weight in either pounds (lbs) or kilograms (kg)? ***Please select answer below:***

❑**Less than 60kg (132lbs)**: Does the prescriber agree to administer Stelara within the FDA labeled maintenance dose of 0.75mg/kg subcutaneously every 12 weeks? ❑Yes ❑No

❑**60kg (132lbs) to 100kg (220lbs)**: Does the prescriber agree to administer Stelara within the FDA labeled maintenance dose of 45mg subcutaneously every 12 weeks? ❑Yes ❑No

❑**Greater than 100kg (220lbs):** Does the prescriber agree to administer Stelara within the FDA labeled maintenance dose of 90 mg subcutaneously every 12 weeks? ❑Yes ❑No

e. **Age 18 or Older**: What is the patient's weight in either pounds (lbs) or kilograms (kg)? ***Please select answer below:***

❑**100kg (220lbs) or less**: Does the prescriber agree to administer Stelara within the FDA labeled maintenance dose of 45mg subcutaneously every 12 weeks? ❑Yes ❑No

❑**Greater than 100kg (221lbs):** Does the prescriber agree to administer Stelara within the FDA labeled maintenance dose of 90 mg subcutaneously every 12 weeks? ❑Yes ❑No

❑ Psoriatic Arthritis (PsA)

a. Does the patient have a diagnosis of active psoriatic arthritis? ❑Yes ❑No

b. Does the patient have an intolerance or contraindication or have they had an inadequate treatment response to a three month trial of at least one conventional DMARD? ❑Yes ❑No

c. **Age 6-17**: What is the patient's weight in either pounds (lbs) or kilograms (kg)? ***Please select answer below:***

❑**Less than 60kg (132lbs)**: Does the prescriber agree to administer Stelara within the FDA labeled maintenance dose of 0.75mg/kg subcutaneously every 12 weeks? ❑Yes ❑No

❑**60kg (132lbs) to 100kg (220lbs)**: Does the prescriber agree to administer Stelara within the FDA labeled maintenance dose of 45mg subcutaneously every 12 weeks? ❑Yes ❑No

❑**Greater than 100kg (220lbs):** Does the patient have a concurrent diagnosis of moderate to severe plaque psoriasis?

❑**Yes**: Does the prescriber agree to administer Stelara within the FDA labeled maintenance dose of 90mg subcutaneously every 12 weeks? ❑Yes ❑No

❑**No:** Does the prescriber agree to administer Stelara within the FDA labeled maintenance dose of 45mg subcutaneously every 12 weeks? ❑Yes ❑No

d. **Age 18 or Older**: What is the patient's weight in either pounds (lbs) or kilograms (kg)? ***Please select answer below:***

❑**Less than or equal to 100kg (220lbs)**: Does the prescriber agree to administer Stelara within the FDA labeled maintenance dose of 45mg subcutaneously every 12 weeks? ❑Yes ❑No

❑**Greater than 100kg (220lbs)**: Does the patient have a concurrent diagnosis of moderate to severe plaque psoriasis?

❑**Yes**: Does the prescriber agree to administer Stelara within the FDA labeled maintenance dose of 90mg subcutaneously every 12 weeks? ❑Yes ❑No

❑**No:** Does the prescriber agree to administer Stelara within the FDA labeled maintenance dose of 45mg subcutaneously every 12 weeks? ❑Yes ❑No

❑ Ulcerative Colitis (UC)

a. Does the patient have a diagnosis of moderate to severely active ulcerative colitis? ❑Yes ❑No

b. Does the patient have an intolerance or contraindication or have they had an inadequate treatment response to at least one conventional therapy option? ❑Yes ❑No

c. Will the patient's first dose be given as an IV infusion? ❑Yes ❑No

d. What is the patient's weight in either pounds (lbs) or kilograms (kg)? ***Please select answer below:***

❑**55kg (121lbs) or less**: Does the prescriber agree to administer 260mg for the initial IV infusion? ❑Yes ❑No

❑**Greater than 55kg (121lbs) to 85kg (187lbs)**: Does the prescriber agree to administer 390mg for the initial IV infusion? ❑Yes ❑No

❑**Greater than 85kg (187lbs)**: Does the prescriber agree to administer 520mg for the initial infusion? ❑Yes ❑No

e. Following the initial IV infusion, does the prescriber agree to administer Stelara within the FDA labeled maintenance dose of 90mg subcutaneously every eight weeks? ❑Yes ❑No

❑ Other diagnosis ***(please specify):*** _____

CONTINUATION OF THERAPY (PA RENEWAL)
Stelara (ustekinumab)

NOTE: Form must be completed in its **entirety** for processing

1. Has the patient been on Stelara continuously for the last **6 months**, excluding samples? ***Please select answer below:***

❑**NO** – this is **INITIATION** of therapy, please answer the questions on **Initiation section.**

❑**YES** – this is a PA renewal for **CONTINUATION** of therapy, please answer the questions below:

2. Has the patient's condition improved or stabilized with Stelara? ❑Yes ❑No
3. Does the patient have any active infections including active tuberculosis (TB) and hepatitis B virus (HBV) infection? ❑Yes ❑No
4. Will the patient be given live vaccines while on Stelara? ❑Yes ❑No
5. Will Stelara be used in combination with another biologic *disease-modifying antirheumatic drug (DMARD) or targeted synthetic DMARD? ❑Yes* ❑No ***If YES***, please specify:_____

DMARDs: Actemra, Avsola, Cimzia, Cosentyx, Enbrel, Entyvio, Humira, Ilumya, Inflectra, Kevzara, Kineret, Olumiant, Orencia, Otezla, Remicade, Renflexis, Riabni, Rinvoq, Rituxan, Ruxience, Siliq, Simponi/Simponi Aria, Skyrizi, Taltz, Tremfya, Truxima, and Xeljanz/Xeljanz XR

6. What is the patient's diagnosis?

❑Crohn's Disease (CD)

a. Does the prescriber agree to administer Stelara within the FDA labeled maintenance dose of 90mg subcutaneously every eight weeks? ❑Yes ❑No

❑Plaque Psoriasis (PsO)

a. **Age 6-17**: What is the patient's weight in either pounds (lbs) or kilograms (kg)? ***Please select answer below:***

❑**Less than 60kg (132lbs)**: Does the prescriber agree to administer Stelara within the FDA labeled maintenance dose of 0.75mg/kg subcutaneously every 12 weeks? ❑Yes ❑No

❑**60kg (132lbs) to 100kg (220lbs)**: Does the prescriber agree to administer Stelara within the FDA labeled maintenance dose of 45mg subcutaneously every 12 weeks? ❑Yes ❑No

❑**Greater than 100kg (220lbs):** Does the prescriber agree to administer Stelara within the FDA labeled maintenance dose of 90 mg subcutaneously every 12 weeks? ❑Yes ❑No

b. **Age 18 or Older**: What is the patient's weight in either pounds (lbs) or kilograms (kg)? ***Please select answer below:***

❑**100kg (220lbs) or less**: Does the prescriber agree to administer Stelara within the FDA labeled maintenance dose of 45mg subcutaneously every 12 weeks? ❑Yes ❑No

❑**Greater than 100kg (220lbs):** Does the prescriber agree to administer Stelara within the FDA labeled maintenance dose of 90 mg subcutaneously every 12 weeks? ❑Yes ❑No

❑Psoriatic Arthritis (PsA)

a. **Age 6-17**: What is the patient's weight in either pounds (lbs) or kilograms (kg)? ***Please select answer below:***

❑**Less than 60kg (132lbs)**: Does the prescriber agree to administer Stelara within the FDA labeled maintenance dose of 0.75mg/kg subcutaneously every 12 weeks? ❑Yes ❑No

❑**60kg (132lbs) to 100kg (220lbs)**: Does the prescriber agree to administer Stelara within the FDA labeled maintenance dose of 45mg subcutaneously every 12 weeks? ❑Yes ❑No

❑**Greater than 100kg (220lbs):** Does the patient have a concurrent diagnosis of moderate to severe plaque psoriasis?

❑**Yes**: Does the prescriber agree to administer Stelara within the FDA labeled maintenance dose of 90mg subcutaneously every 12 weeks? ❑Yes ❑No

❑**No:** Does the prescriber agree to administer Stelara within the FDA labeled maintenance dose of 45mg subcutaneously every 12 weeks? ❑Yes ❑No

b. **Age 18 or Older**: What is the patient's weight in either pounds (lbs) or kilograms (kg)? ***Please select answer below:***

❑**Less than or equal to 100kg (220lbs)**: Does the prescriber agree to administer Stelara within the FDA labeled maintenance dose of 45mg subcutaneously every 12 weeks? ❑Yes ❑No

❑**Greater than 100kg (220lbs)**: Does the patient have a concurrent diagnosis of moderate to severe plaque psoriasis?

❑**Yes**: Does the prescriber agree to administer Stelara within the FDA labeled maintenance dose of 90mg subcutaneously every 12 weeks? ❑Yes ❑No

❑**No:** Does the prescriber agree to administer Stelara within the FDA labeled maintenance dose of 45mg subcutaneously every 12 weeks? ❑Yes ❑No

❑Ulcerative Colitis (UC)

a. Does the prescriber agree to administer Stelara within the FDA labeled maintenance dose of 90mg subcutaneously every eight weeks? ❑Yes ❑No

❑Other diagnosis ***(please specify):*** _____

Chart notes are required for the processing of all requests. Please add any other supporting medical information necessary for our review **(required)**

Coverage will not be provided if the prescribing physician's signature and date are not reflected on this document.

❑ Request for expedited review: I certify that applying the standard review time frame may seriously jeopardize the life or health of the member or the member's ability to regain maximum function

Physician's Name	**Physician Signature**	**Date**
Step 2: Checklist	❑ Form Completely Filled Out ❑ Provide chart notes	❑ Attach test results
Step 3: Submit	**By Fax: BCBSM Specialty Pharmacy Mailbox** **1-877-325-5979**	**By Mail: BCBSM Specialty Pharmacy Program** **P.O. Box 312320, Detroit, MI 48231-2320**